Entrada Therapeutics Net Income
| TRDA Stock | USD 10.80 0.27 2.44% |
As of the 14th of February 2026, Entrada Therapeutics shows the Downside Deviation of 3.01, coefficient of variation of 492.42, and Mean Deviation of 2.96. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Entrada Therapeutics, as well as the relationship between them.
Entrada Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.246 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 75.5 M | 79.2 M | |
| Net Loss | -85.2 M | -80.9 M | |
| Net Income | 75.5 M | 79.2 M | |
| Net Income Per Share | 1.58 | 1.66 | |
| Net Income Per E B T | 0.89 | 0.93 |
Entrada | Net Income | Build AI portfolio with Entrada Stock |
Analyzing Entrada Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Entrada Therapeutics's current valuation and future prospects.
Latest Entrada Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Entrada Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Entrada Therapeutics financial statement analysis. It represents the amount of money remaining after all of Entrada Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Entrada Therapeutics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entrada Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 65.63 M | 10 Years Trend |
|
Net Income |
| Timeline |
Entrada Net Income Regression Statistics
| Arithmetic Mean | 183,076 | |
| Geometric Mean | 11,697,405 | |
| Coefficient Of Variation | 22,605 | |
| Mean Deviation | 25,857,655 | |
| Median | (4,649,000) | |
| Standard Deviation | 41,383,607 | |
| Sample Variance | 1712.6T | |
| Range | 166.7M | |
| R-Value | 0.34 | |
| Mean Square Error | 1617.3T | |
| R-Squared | 0.11 | |
| Significance | 0.18 | |
| Slope | 2,774,982 | |
| Total Sum of Squares | 27401.6T |
Entrada Net Income History
Other Fundumenentals of Entrada Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Entrada Therapeutics Net Income component correlations
Entrada Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Entrada Therapeutics is extremely important. It helps to project a fair market value of Entrada Stock properly, considering its historical fundamentals such as Net Income. Since Entrada Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Entrada Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Entrada Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Entrada Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.57) | Revenue Per Share | Quarterly Revenue Growth (0.92) | Return On Assets | Return On Equity |
Understanding Entrada Therapeutics requires distinguishing between market price and book value, where the latter reflects Entrada's accounting equity. The concept of intrinsic value - what Entrada Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Entrada Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Entrada Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Entrada Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Entrada Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Entrada Therapeutics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Entrada Therapeutics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Entrada Therapeutics or generate 0.0% return on investment in Entrada Therapeutics over 90 days. Entrada Therapeutics is related to or competes with Humacyte, Achieve Life, Voyager Therapeutics, Vanda Pharmaceuticals, Atea Pharmaceuticals, Arcturus Therapeutics, and Capricor Therapeutics. Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle therapeutics for the treatment of... More
Entrada Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Entrada Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Entrada Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.01 | |||
| Information Ratio | 0.184 | |||
| Maximum Drawdown | 18.48 | |||
| Value At Risk | (4.08) | |||
| Potential Upside | 6.65 |
Entrada Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entrada Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Entrada Therapeutics' standard deviation. In reality, there are many statistical measures that can use Entrada Therapeutics historical prices to predict the future Entrada Therapeutics' volatility.| Risk Adjusted Performance | 0.1717 | |||
| Jensen Alpha | 0.7587 | |||
| Total Risk Alpha | 0.462 | |||
| Sortino Ratio | 0.2238 | |||
| Treynor Ratio | (1.81) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entrada Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Entrada Therapeutics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1717 | |||
| Market Risk Adjusted Performance | (1.80) | |||
| Mean Deviation | 2.96 | |||
| Semi Deviation | 2.69 | |||
| Downside Deviation | 3.01 | |||
| Coefficient Of Variation | 492.42 | |||
| Standard Deviation | 3.67 | |||
| Variance | 13.43 | |||
| Information Ratio | 0.184 | |||
| Jensen Alpha | 0.7587 | |||
| Total Risk Alpha | 0.462 | |||
| Sortino Ratio | 0.2238 | |||
| Treynor Ratio | (1.81) | |||
| Maximum Drawdown | 18.48 | |||
| Value At Risk | (4.08) | |||
| Potential Upside | 6.65 | |||
| Downside Variance | 9.08 | |||
| Semi Variance | 7.25 | |||
| Expected Short fall | (3.66) | |||
| Skewness | 0.2592 | |||
| Kurtosis | 0.1453 |
Entrada Therapeutics Backtested Returns
Entrada Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Entrada Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Entrada Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Entrada Therapeutics' Coefficient Of Variation of 492.42, downside deviation of 3.01, and Mean Deviation of 2.96 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Entrada Therapeutics holds a performance score of 10. The firm shows a Beta (market volatility) of -0.41, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Entrada Therapeutics are expected to decrease at a much lower rate. During the bear market, Entrada Therapeutics is likely to outperform the market. Please check Entrada Therapeutics' value at risk, kurtosis, market facilitation index, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Entrada Therapeutics' price patterns will revert.
Auto-correlation | 0.67 |
Good predictability
Entrada Therapeutics has good predictability. Overlapping area represents the amount of predictability between Entrada Therapeutics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Entrada Therapeutics price movement. The serial correlation of 0.67 indicates that around 67.0% of current Entrada Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.67 | |
| Spearman Rank Test | 0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 0.28 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Entrada Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Entrada Therapeutics reported net income of 65.63 M. This is 80.77% lower than that of the Biotechnology sector and 6.31% lower than that of the Health Care industry. The net income for all United States stocks is 88.51% higher than that of the company.
Entrada Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entrada Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entrada Therapeutics could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics of similar companies.Entrada Therapeutics is currently under evaluation in net income category among its peers.
Entrada Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Entrada Therapeutics from analyzing Entrada Therapeutics' financial statements. These drivers represent accounts that assess Entrada Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Entrada Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 748.4M | 534.6M | 423.1M | 498.7M | 448.9M | 356.8M | |
| Enterprise Value | 709.4M | 243.5M | 403.9M | 499.4M | 449.4M | 298.3M |
Entrada Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Entrada Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Entrada Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Entrada Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Entrada Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Entrada Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Entrada Therapeutics' value.| Shares | Fmr Inc | 2025-06-30 | 496.1 K | State Street Corp | 2025-06-30 | 495.9 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 424 K | Renaissance Technologies Corp | 2025-06-30 | 379.5 K | Northern Trust Corp | 2025-06-30 | 300.3 K | Royce & Associates, Lp | 2025-06-30 | 223.3 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 220.7 K | Charles Schwab Investment Management Inc | 2025-06-30 | 203.7 K | Millennium Management Llc | 2025-06-30 | 170.3 K | Baker Bros Advisors Lp | 2025-06-30 | 4.9 M | Mpm Asset Management, Llc | 2025-06-30 | 4.4 M |
Entrada Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.68) % | ||||
| Operating Margin | (29.15) % | ||||
| Current Valuation | 138.18 M | ||||
| Shares Outstanding | 38.22 M | ||||
| Shares Owned By Insiders | 12.23 % | ||||
| Shares Owned By Institutions | 77.88 % | ||||
| Number Of Shares Shorted | 896.14 K | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 6.71 X | ||||
| Revenue | 210.78 M | ||||
| Gross Profit | (80.2 M) | ||||
| EBITDA | 50.78 M | ||||
| Net Income | 65.63 M | ||||
| Cash And Equivalents | 244.25 M | ||||
| Cash Per Share | 7.81 X | ||||
| Total Debt | 59.21 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 14.05 X | ||||
| Book Value Per Share | 9.50 X | ||||
| Cash Flow From Operations | (41.56 M) | ||||
| Short Ratio | 3.62 X | ||||
| Earnings Per Share | (2.57) X | ||||
| Target Price | 18.5 | ||||
| Number Of Employees | 183 | ||||
| Beta | -0.12 | ||||
| Market Capitalization | 412.77 M | ||||
| Total Asset | 526.32 M | ||||
| Retained Earnings | (129.34 M) | ||||
| Working Capital | 400.56 M | ||||
| Net Asset | 526.32 M |
About Entrada Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Entrada Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entrada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entrada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Entrada Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.57) | Revenue Per Share | Quarterly Revenue Growth (0.92) | Return On Assets | Return On Equity |
Understanding Entrada Therapeutics requires distinguishing between market price and book value, where the latter reflects Entrada's accounting equity. The concept of intrinsic value - what Entrada Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Entrada Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Entrada Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.